Pythia BioSciences and Lexogen Partner to Unify Multi-Omics Data Curation and Analytics with Bulk and Single-Cell RNA Sequencing
Pythia BioSciences and Lexogen recently announced a strategic partnership to empower researchers with deeper biological insights by combining Lexogen’s expertise in RNA sequencing and library preparation with Pythia’s multi-omics data curation and analytics capabilities.
Through this collaboration, Pythia will offer Lexogen’s wet-lab capabilities via direct sales and as a core component of its newly launched expanded data ecosystem focused on maximising proprietary data generation and cohort building through a global network of biobank sample providers and multi-omics wet-lab partners. Together, Lexogen and Pythia aim to accelerate the drug discovery and development pipeline, enabling biopharma teams to rapidly transform complex biological samples into actionable therapeutic insights.
Combining public datasets with custom data generation
While high-quality public datasets from Pythia are valuable for drug discovery, finding cohorts that match specific therapeutic questions can be difficult. Public repositories are often limited by disease representation, sparse treatment metadata and small patient sizes.
The Pythia-Lexogen partnership aims to address these hurdles by combining advanced analytics and standardized data curation workflows with Lexogen’s streamlined, custom wet-lab data generation.
Three phases of data exploration and experimental design
The integrated Pythia ecosystem guides researchers through three distinct phases of data exploration and experimental design. First, teams can use Pythiomics to access fully curated, high-quality and harmonized multi-omic public datasets.
To fill specific data gaps, researchers can query the Pythia Data Forge, an incubator repository containing hundreds of thousands of searchable datasets that can be manually quality-controlled and finalized in under a week to expand the active cohort. By combining these criteria-matched datasets, scientists can identify biological signals that can inform future experiments.
Finally, through the Pythia Data Universe, teams can source optimized biobank samples and connect with multi-omics wet-lab providers, enabling custom bulk and single-cell RNA-seq (scRNA-seq) experiments powered by Lexogen.
“Lexogen’s twenty years of proven data excellence and their ability to execute on projects exceeding 100,000 samples make them the ideal partner for Pythia,” said Tristan Gill, CEO of Pythia BioSciences. “Together, we are empowering the scientific community to accelerate drug discovery and deliver life-changing therapies to the patients who need them most.”
Stéphane Barges, CEO of Lexogen, added: “By combining our sequencing expertise with Pythia’s rigorous data harmonization and curation pipeline, we hope to expand both the quantity and diversity of high-quality RNA-seq datasets available to researchers. Ultimately, this will enable more data-driven research with broader biological insights and accelerate more discoveries.”